ABSTRACT
BACKGROUND: Metabolic syndrome (MS) is a complex and prevalent disorder. Oxidative stress and inflammation might contribute to the progression of MS. Soluble ST2 (sST2) is an attractive and druggable molecule that sits at the interface between inflammation, oxidative stress and fibrosis. This study aims to analyze the relationship among sST2, oxidative stress, inflammation and echocardiographic parameters in MS patients. METHODS: Fifty-eight patients with MS were recruited and underwent physical, laboratory and transthoracic echocardiography examinations. Commercial ELISA and appropriate colorimetric assays were used to quantify serum levels of oxidative stress and inflammation markers and sST2. RESULTS: Circulating sST2 was increased in MS patients and was significantly correlated with the oxidative stress markers nitrotyrosine and 8-hydroxy-2'-deoxyguanosine as well as with peroxide levels. The inflammatory parameters interleukin-6, intercellular adhesion molecule-1 and myeloperoxidase were positively correlated with sST2. Noteworthy, sST2 was positively correlated with left ventricular mass, filling pressures and pulmonary arterial pressures. CONCLUSION: Circulating levels of sST2 are associated with oxidative stress and inflammation burden and may underlie the pathological remodeling and dysfunction of the heart in MS patients. Our results suggest that sST2 elevation precedes diastolic dysfunction, emerging as an attractive biotarget in MS.
Subject(s)
Metabolic Syndrome , Humans , Biomarkers , Inflammation , Interleukin-1 Receptor-Like 1 Protein , Oxidative StressABSTRACT
Introducción y objetivos: El desfibrilador automático implantable (DAI) se ha establecido como terapia en pacientes con elevado riesgo de sufrir arritmias ventriculares malignas.Algunos estudios plantean un posible efecto oncogénico de materiales protésicos utilizados. Igualmente, existen trabajos que describen mayor incidencia de cáncer en portadores de DAI y plantean una potencial relación causal entre ambos.El objetivo principal del estudio es describir la incidencia de cáncer en nuestra muestra de pacientes portadores de DAI y compararla con resultados de otras bases de datos.MétodosEstudio de cohortes retrospectivo de pacientes con DAI que se incluyeron en el Complejo Hospitalario de Navarra entre los años 2000 y 2016 y se siguieron hasta junio de 2018.Se analizaron variables sociodemográficas, comorbilidades y datos sobre patología oncológica.Se estimaron tasas de incidencia acumulada (TIA) de cáncer durante el seguimiento que se compararon con datos poblacionales y con datos de otra cohorte de pacientes con insuficiencia cardiaca con FEVI reducida. Se ajustaron modelos de riesgos competitivos para cáncer en el seguimiento.ResultadosSe incluyeron 497 pacientes, mayoritariamente hombres (89,1%) con una edad media de 59,98 (14,98) años, con una proporción de fumadores del 67,6% y de cardiopatía isquémica del 51,6%. La TIA de cáncer fue 1.230,9 por 100.000 personas-año. Las variables que se asociaron significativamente con cáncer fueron mayor edad, mayor consumo de tabaco y cardiopatía isquémica.ConclusionesLa incidencia de cáncer es elevada en pacientes con DAI. Este hallazgo parece relacionado principalmente con el tabaco y la mayor edad. (AU)
Introduction and Objectives: implantable cardiac defibrillator (ICD) has been established as a therapy for malignant ventricular arrhythmias in patients at high risk of suffering them.Some studies suggest a possible relationship between the development of cancer and some prosthetic materials. Likewise, some investigations describe a higher incidence of cancer in patients with an ICD that suggest a potential relationship.MethodsRetrospective cohort study of patients that underwent implantation of an ICD in the Complejo Hospitalario de Navarra between 2000 and 2016. The follow-up finished in June 2018.Sociodemographic, comorbidities and oncological data was analysed. Cancer incidence rates were estimated and compared with the general population data and with data of a cohort of patients with reduced LVEF heart failure. Risk of cancer models were adjusted by competitive risk models.Results497 patients were included, mostly male (89.1%), with a mean age of 59.98 (14.98) years and a proportion of smokers of 67.6% and of ischaemic heart disease of 51.6%. The cancer incidence rate in the sample was 1230.9 per 100.000 person-year. In our study, features associated with cancer were older age, higher tobacco use and ischaemic cardiopathy.ConclusionsIn our sample of ICD carriers the incidence of cancer is high. This finding mainly seems to be related to tobacco usage and higher age. (AU)
Subject(s)
Humans , Arrhythmias, Cardiac/epidemiology , Arrhythmias, Cardiac/etiology , Arrhythmias, Cardiac/therapy , Defibrillators, Implantable/adverse effects , Neoplasms/epidemiology , Neoplasms/therapy , Death, Sudden, Cardiac , Retrospective Studies , Risk FactorsABSTRACT
INTRODUCTION AND OBJECTIVES: implantable cardiac defibrillator (ICD) has been established as a therapy for malignant ventricular arrhythmias in patients at high risk of suffering them. Some studies suggest a possible relationship between the development of cancer and some prosthetic materials. Likewise, some investigations describe a higher incidence of cancer in patients with an ICD that suggest a potential relationship. METHODS: Retrospective cohort study of patients that underwent implantation of an ICD in the Complejo Hospitalario de Navarra between 2000 and 2016. The follow-up finished in June 2018. Sociodemographic, comorbidities and oncological data was analysed. Cancer incidence rates were estimated and compared with the general population data and with data of a cohort of patients with reduced LVEF heart failure. Risk of cancer models were adjusted by competitive risk models. RESULTS: 497 patients were included, mostly male (89.1%), with a mean age of 59.98 (14.98) years and a proportion of smokers of 67.6% and of ischaemic heart disease of 51.6%. The cancer incidence rate in the sample was 1230.9 per 100.000 person-year. In our study, features associated with cancer were older age, higher tobacco use and ischaemic cardiopathy. CONCLUSIONS: In our sample of ICD carriers the incidence of cancer is high. This finding mainly seems to be related to tobacco usage and higher age.
Subject(s)
Defibrillators, Implantable , Neoplasms , Aged , Arrhythmias, Cardiac/epidemiology , Arrhythmias, Cardiac/etiology , Arrhythmias, Cardiac/therapy , Death, Sudden, Cardiac , Defibrillators, Implantable/adverse effects , Female , Humans , Male , Middle Aged , Neoplasms/epidemiology , Neoplasms/therapy , Retrospective Studies , Risk Factors , Treatment OutcomeABSTRACT
No disponible
Subject(s)
Humans , Female , Adolescent , Fistula/diagnostic imaging , Fistula/surgery , Atrial Appendage/diagnostic imaging , Heart Ventricles/diagnostic imaging , Heart Ventricles/pathology , Wolff-Parkinson-White Syndrome/complications , Wolff-Parkinson-White Syndrome/diagnostic imaging , Atrial Appendage/surgery , Echocardiography/methods , Cardiac Electrophysiology/methods , Atrial Fibrillation/diagnostic imaging , Atrial Fibrillation/surgery , Thoracoscopy/methodsSubject(s)
Atrial Appendage , Fistula/complications , Heart Ventricles , Wolff-Parkinson-White Syndrome/etiology , Adolescent , Cardiac Surgical Procedures , Catheter Ablation , Computed Tomography Angiography , Electrocardiography , Fistula/diagnosis , Fistula/surgery , Heart Conduction System/physiopathology , Humans , Imaging, Three-Dimensional , Wolff-Parkinson-White Syndrome/diagnosis , Wolff-Parkinson-White Syndrome/surgeryABSTRACT
No disponible
Subject(s)
Humans , Female , Aged, 80 and over , Aortic Valve Stenosis/surgery , Transcatheter Aortic Valve Replacement , Postoperative Complications , Cardiac Tamponade/etiologySubject(s)
Aortic Rupture/etiology , Aortic Valve Stenosis/surgery , Aortic Valve/surgery , Postoperative Complications , Transcatheter Aortic Valve Replacement/adverse effects , Aged, 80 and over , Aortic Rupture/diagnosis , Aortic Valve Stenosis/diagnosis , Echocardiography , Fatal Outcome , Female , HumansABSTRACT
BACKGROUND: A biomarker that is of great interest in relation to adverse cardiovascular events is soluble ST2 (sST2), a member of the interleukin family. Considering that metabolic syndrome (MetS) is accompanied by a proinflammatory state, we aimed to assess the relationship between sST2 and left ventricular (LV) structure and function in patients with MetS. METHODS: A multicentric, cross-sectional study was conducted on180 MetS subjects with normal LV ejection fraction as determined by echocardiography. LV hypertrophy (LVH) was defined as an LV mass index greater than the gender-specific upper limit of normal as determined by echocardiography. LV diastolic dysfunction (DD) was assessed by pulse-wave and tissue Doppler imaging. sST2 was measured by using a quantitative monoclonal ELISA assay. RESULTS: LV mass index (ß=0.337, P<0.001, linear regression) was independently associated with sST2 concentrations. Increased sST2 was associated with an increased likelihood of LVH [Exp (B)=2.20, P=0.048, logistic regression] and increased systolic blood pressure [Exp (B)=1.02, P=0.05, logistic regression]. Comparing mean sST2 concentrations (adjusted for age, body mass index, gender) between different LV remodeling patterns, we found the greatest sST2 level in the group with concentric hypertrophy. There were no differences in sST2 concentration between groups with and without LV DD. CONCLUSIONS: Increased sST2 concentration in patients with MetS was associated with a greater likelihood of exhibiting LVH. Our results suggest that inflammation could be one of the principal triggering mechanisms for LV remodeling in MetS.
